Mauricio Castillo-Salazar

Dr. Mauricio Castillo-Salazar


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
MCMauricio Castillo-Salazar
Mauricio Castillo-Salazar
Fausto Sanchez-MunozFausto Sanchez-Munoz
Fausto Sanchez-Munoz
RSRASHIDI SPRINGALL
RASHIDI SPRINGALL
Gabriel Navarrete-VazquezGabriel Navarrete-Vazquez
Gabriel Navarrete-Vazquez
Adrián Hernández-DíazcouderAdrián Hernández-Díazcouder
Adrián Hernández-Díazcouder
GBGermán Bernal-Fernández
Germán Bernal-Fernández
Background: Type 2 diabetes (T2D) is a low-grade inflammatory condition with abnormalities in the immune response mediated by T lymphocytes and macrophages. Drug repositioning for immunomodulatory molecules is an attractive proposal for treating T2D. Nitazoxanide (NTZ) is a broad-spectrum drug with promising immunomodulatory effects. Thus, we investigated the immunomodulatory effect of NTZ on peripheral blood mononuclear cells (PBMCs) from patients with T2D. Methods: Fifty patients with T2D were selected, and the proliferative response of T lymphocytes and the M1/M2 ratio of macrophages post cell culture were evaluated by flow cytometry, as well as measuring the concentration of cytokines by ELISA and the relative expression of microRNAs (miRNAs) related to the immune response by real-time PCR. Results: NTZ exerts an inhibitory effect on the cell proliferation of T lymphocytes stimulated with anti-CD3 and anti-CD28 antibodies without modifying cell viability, and significant decreases in the supernatant concentrations of interleukin (IL)-1β, IL-2, IL-6, IL-10, and IL-12. Furthermore, NTZ negatively regulates the relative expression of miR-155-5p without changes in miR-146a-5p. The M1/M2 ratio of monocytes/macrophages decreased the M1 and increased the M2 subpopulation by NTZ. Conclusions: Our results suggest that NTZ exerts immunomodulatory effects on PBMCs from T2D patients, and shows potential alternative therapeutic benefits.